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Life for the vertebrate requires sustained and rhythmic beat-ing of the heart for delivery of oxygen and nutrients to 
the brain and other organs. The vertebrate cardiomyocyte has 
evolved elegant membrane regulatory pathways to maintain effi-
cient excitation-contraction coupling at baseline or in the face of 
acute and chronic stress. Central to this membrane regulation is 
the cardiac cytoskeleton. In the heart, the cytoskeletal network 
comprises a highly ordered array of structural and accessory 
proteins spanning from the plasma membrane to the nucleus.
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Background—The cardiac cytoskeleton plays key roles in maintaining myocyte structural integrity in health and disease. In 
fact, human mutations in cardiac cytoskeletal elements are tightly linked to cardiac pathologies, including myopathies, 
aortopathies, and dystrophies. Conversely, the link between cytoskeletal protein dysfunction and cardiac electric activity 
is not well understood and often overlooked in the cardiac arrhythmia field.
Methods and Results—Here, we uncover a new mechanism for the regulation of cardiac membrane excitability. We report 
that βII spectrin, an actin-associated molecule, is essential for the posttranslational targeting and localization of critical 
membrane proteins in heart. βII spectrin recruits ankyrin-B to the cardiac dyad, and a novel human mutation in the ankyrin-B 
gene disrupts the ankyrin-B/βII spectrin interaction, leading to severe human arrhythmia phenotypes. Mice lacking cardiac 
βII spectrin display lethal arrhythmias, aberrant electric and calcium handling phenotypes, and abnormal expression/
localization of cardiac membrane proteins. Mechanistically, βII spectrin regulates the localization of cytoskeletal and 
plasma membrane/sarcoplasmic reticulum protein complexes, including the Na/Ca exchanger, ryanodine receptor 2, 
ankyrin-B, actin, and αII spectrin. Finally, we observe accelerated heart failure phenotypes in βII spectrin–deficient mice.
Conclusions—Our findings identify βII spectrin as critical for normal myocyte electric activity, link this molecule to human 
disease, and provide new insight into the mechanisms underlying cardiac myocyte biology. (Circulation. 2015;131:695-708. 
DOI: 10.1161/CIRCULATIONAHA.114.013708.)
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Over the past 2 decades, the cardiac cytoskeleton has 
emerged as a central governing factor in the control of car-
diac membrane integrity, and dysfunction in cytoskeleton 
and cytoskeleton-associated proteins has been directly linked 
to a host of human cardiac pathologies, most notably car-
diac myopathies and dystrophies. In fact, human mutations 
in cardiac cytoskeletal or cytoskeleton-associated genes that 
alter myocyte signal transduction, myocardial mechanics, 
and force transmission are now directly linked to dilated 
cardiomyopathy, muscular dystrophy, and arrhythmogenic 
cardiomyopathy.1–4
In contrast to myopathy and dystrophy fields, the role of 
the cytoskeleton in normal cardiac electric function is not well 
resolved. Furthermore, until the last decade, human arrhythmia 
mechanisms were limited primarily to mutations in cardiac ion 
channels.5 However, although literally hundreds of human vari-
ants in cardiac Na+, K+, and Ca2+ channel α and β subunits have 
been linked to sinus node disease, atrial fibrillation, conduction 
disease, and ventricular fibrillation, a second class of human 
arrhythmias has emerged resulting from mutations in ion 
channel–associated proteins, including α-syntrophin, ankyrin-
G, caveolin-3, fibroblast growth factor-12, and ankyrin-B.6 
Mechanistically, dysfunction in these proteins is linked to 
diverse cellular pathologies, including defects in channel syn-
thesis and membrane targeting, channel gating, and channel 
posttranslational modifications. Although this information has 
been important for new disease diagnosis and fundamental 
cardiac cell biology, there remain large cohorts of phenotype-
positive/genotype-negative patients with familial forms of car-
diac arrhythmia. Furthermore, pressing unanswered questions 
remain on the role for the cardiac cytoskeleton for the local 
organization of membrane ion channel complexes in vivo.
On the basis of genetic findings in a proband with severe 
ventricular arrhythmia and cardiac arrest, we uncovered a new 
and essential cytoskeleton-based pathway critical for cardiac 
electric function. We identify βII spectrin as an integral regu-
latory node for the organization of critical myocyte membrane 
and membrane-associated proteins. βII spectrin is critical 
for the regulation of ankyrin-B and αII spectrin, and defects 
in this assembly result in severe arrhythmia associated with 
aberrant calcium phenotypes. Moreover, we link dysfunction 
in this pathway to accelerated heart failure phenotypes. In 
summary, our findings provide a new mechanism for human 
excitable cell disease and uncover new roles for the cardiac 
cytoskeleton in human cardiovascular disease.
Methods
Statistics
Data are presented as mean±SEM. For the comparison of 2 groups, we 
performed Wilcoxon-Mann-Whitney U tests. For the comparison of >2 
groups, we applied a Kruskal-Wallis test. When we obtained a signifi-
cant P value, we continued with pair-wise comparisons using Wilcoxon-
Mann-Whitney U tests according to the closed-testing principle. For our 
study, a value of P<0.05 was considered statistically significant.
Human Studies
Approval for use of human subjects was obtained from the 
Institutional Review Board of Ohio State University, and subjects 
provided informed consent. 
Animal Studies
Procedures followed were approved and were in accordance with 
institutional guidelines (Ohio State University)
Additional methods are provided in the online-only Data 
Supplement.
Results
Identification of a New Class of ANK2 Human 
Arrhythmia Mutation
Human ANK2 variants cause cardiac arrhythmia phenotypes, 
including sinus node disease, atrial fibrillation, conduction 
block, ventricular arrhythmia, syncope, and sudden car-
diac death.7–11 We identified a new class of ANK2 variant in 
a proband with a severe history of recurrent sudden cardiac 
arrest resulting from ventricular fibrillation (Figure 1A). The 
proband is a 36-year-old woman with prolonged QTc on her 
ECG who suffered an out-of-hospital cardiac arrest caused 
by ventricular fibrillation. After resuscitation, she underwent 
implantation of a transvenous, dual-chamber, implantable 
cardioverter-defibrillator. Since her first event, she has had 
recurrent ventricular fibrillation, resulting in syncope and 
implantable cardioverter-defibrillator shocks, with implant-
able cardioverter-defibrillator interrogation demonstrating 
premature ventricular complexes preceding episodes of ven-
tricular fibrillation. In addition to prolonged QTc interval 
(Figure 1B), the individual displays regular premature ven-
tricular complexes (Figure 1C), both harbingers of poten-
tial arrhythmic events. Initial genetic testing for variants in 
KCNQ1, KCNH2, SCN5A, KCNE1, and KCNE2 was negative 
for deleterious mutations. Subsequent genetic testing using 
an extended sequencing panel including 5 additional genes 
(ANK2, KCNJ2, CAV3, RYR2, and CASQ2) revealed an ANK2 
c.2969G>A change, resulting in the substitution of Arg to Gln 
at position 990 (p.R990Q). Exon array of ANK2 and other 
genes previously tested by sequencing analysis did not detect 
any deletions or duplications. The c.2969G>A variant is rare 
across multiple populations with a minor allele frequency of 
≈0.007% (0 per 4406 African American alleles, 1 per 8599 
European American alleles; National Heart, Lung, and Blood 
Institute Exome Sequencing Project). Notably, R990 is highly 
conserved from humans to zebrafish, roundworms, and fruit 
flies (Figure 1D), and structural modeling reveals that the 
p.R990Q variant is juxtaposed to the central ZU5 binding 
surface for βII spectrin (Figure 1A and 1E).12 This region of 
ankyrin has not previously been linked to disease and in fact 
is >1500 base pairs from any previously identified variant 
(Figure 1A, 1D, and 1E).
Ankyrin-B and βII Spectrin Are Molecular Partners 
in Human Heart
A requisite function of a canonical ankyrin polypeptide is asso-
ciation with the α/β spectrin heterotetramer. This complex, by 
association with actin (via spectrin), functionally couples inte-
gral membrane proteins (ion channels, receptors, transporters) 
with the cytoskeletal infrastructure. Ankyrins associate with 
β spectrin gene products through conserved residues in the 
N-terminal ZU5 (Zu5N) domain.12 On the basis of the location 
of the human variant, we tested the functional relationship 
 by guest on D
ecem
ber 23, 2016
http://circ.ahajournals.org/
D
ow
nloaded from
 
Smith et al  Cytoskeletal Defects in Arrhythmia  697
between ankyrin-B and βII spectrin. βII spectrin is normally 
localized at myocyte T tubules (Figure 2A and Figure I in the 
online-only Data Supplement) with ankyrin-B.13 Ankyrin-B 
directly associates with radiolabeled βII spectrin (Figure 2B), 
and βII spectrin coimmunoprecipitates with ankyrin-B from 
detergent-soluble lysates from adult mouse heart and nonfail-
ing human heart (Figure 2C and 2D). We observed a larger 
macromolecular complex between ankyrin-B and βII spectrin 
with membrane proteins, including the Na+/K+ ATPase and 
Na+/Ca2+ exchanger (ankyrin-binding partners), as well as the 
cytoskeletal element actin by coimmunoprecipitation experi-
ments from both mouse and human heart (Figure 2C and 2D). 
These data demonstrate the presence of a βII spectrin/ankyrin-
B cytoskeletal complex in heart.
We hypothesized that the human p.R990Q variant confers 
susceptibility to cardiac arrhythmia by altering ankyrin-B 
binding for βII spectrin, thus affecting integration of mem-
brane proteins with the cytoskeleton.12,14 Whereas wild-type 
ankyrin-B robustly associated with βII spectrin, we observed a 
significant decrease in binding of ankyrin-B p.R990Q with βII 
spectrin (Figure 2E and 2F). In silico modeling for the human 
p.R990Q variant with the costructure for ankyrin-B and βII 
spectrin revealed that the R990 forms several hydrogen bonds 
and salt bridges with surrounding residues, a property strictly 
conserved in all ankyrins (Figure 2G). Moreover, modeling 
revealed that p.R990Q results in loss of salt bridge interactions 
with surrounding residues (Figure 2G). Ankyrin-B p.R990Q 
may directly disrupt βII spectrin binding. Alternatively, on 
the basis of the localization of the residue, this mutation may 
destabilize the folding of the ZU5 domain, resulting indirectly 
in the loss of spectrin binding and overall loss of ankyrin-B 
function.
Analysis of Human Variants That Block βII 
Spectrin Binding in Myocytes
We tested the relationship between human ankyrin-B vari-
ants and βII spectrin in primary myocytes. Because mice 
lacking global ankyrin-B expression die in utero or shortly 
after birth, thus limiting the ability to study ankyrin-
dependent mechanisms past postnatal day 2, we generated 
a new mouse model homozygous for a conditional cardiac 
ankyrin-B–null allele (αMHC-Cre; ankyrin-B conditional 
knockout [cKO] mouse; Figure II in the online-only Data 
Supplement). The null allele was created by targeting Ank2 
exon 24 disrupting all known Ank2 splice products. The 
mutant allele was confirmed by Southern blot and poly-
merase chain reaction strategies (Figure IIB in the online-
only Data Supplement), and myocytes from ankyrin-B cKO 
mice display loss of ankyrin-B protein by immunoblot and 
immunostaining (Figure IIC–IIF in the online-only Data 
Supplement). Using well-differentiated primary neonatal 
ankyrin-B cKO myocytes (postnatal day 7), we tested the 
Figure 1. Ankyrin-B arrhythmia variant identified in 
conserved spectrin-binding domain. A, Ankyrin-B 
includes ANK repeats, a spectrin-binding domain 
comprising 2 ZU5 and 1 UPA domain, and a 
regulatory domain comprising a death and 
C terminus. Identified ANK2 loss-of-function 
mutations are noted by blue arrows, and the novel 
p.R990Q variant is indicated in red. B, ANK2 
p.R990Q proband displays QT prolongation. C, A 
10-second rhythm strip in the p.R990Q proband 
demonstrating atrial demand pacing (black arrows) 
with premature ventricular contraction (red arrow). 
D, Sequence alignment of ankyrin-B spectrin-
binding sequence. Residues that are absolutely 
conserved and highly conserved are in blue and 
green, respectively. Secondary structural elements 
are indicated above the alignment. p.R990Q is 
conserved across species and marked with “o.” 
E, Structure of the ZU5N-UPA tandem of ankyrin-B 
spectrin-binding domain reveals the spectrin-
binding surface and location of p.R990 (green).
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activity of the p.R990Q variant. Wild-type ankyrin-B–green 
fluorescent protein or human ankyrin-B variant p.R990Q 
was introduced into ankyrin-B cKO myocytes. Notably, 
compared with control wild-type myocytes (Figure IIIA and 
IIIB in the online-only Data Supplement), ankyrin-B cKO 
myocytes display loss of targeting of Na+/Ca2+ exchanger, a 
known binding partner in heart (Figure IIIC and IIID in the 
online-only Data Supplement). Green fluorescent protein–
ankyrin-B was striated when expressed in ankyrin-B cKO 
myocytes and was sufficient to rescue the localization of the 
Na+/Ca2+ exchanger (Figure IIIE and IIIF in the online-only 
Data Supplement). In contrast, ankyrin-B p.R990Q, simi-
lar to 2 ankyrin-B mutants previously identified as lacking 
spectrin binding (A1000P and DAR976AAA),13 was not 
appropriately targeted (diffuse cytoplasmic expression) and 
failed to rescue the localization of the Na+/Ca2+ exchanger 
(Figure IIIG–IIIL in the online-only Data Supplement).
βII Spectrin cKO Mice Display Sinus Node 
Dysfunction and Ventricular Arrhythmia
The functional role for βII spectrin for postnatal cardiac func-
tion in vivo is unknown and untested. We therefore examined 
cardiac electric phenotypes in a new mouse model with con-
ditional deletion of cardiac βII spectrin (βII spectrin cKO; 
Figure 3A). βII spectrin cKO mice lack βII spectrin in heart 
but not in other tissues (Figure 3B–3F). Telemetry studies 
of conscious mice show reduced heart rate, increased heart 
rate variability, atrioventricular block, and proarrhythmic 
ECG phenotypes (widened QRS complexes, prolonged QT 
interval) in βII spectrin cKO mice compared with wild-type 
littermates at baseline (Figure 4A–4H). Notably, catechol-
aminergic stress (exercise or low-dose epinephrine) resulted 
in pronounced ventricular arrhythmia (both nonsustained 
and sustained episodes) and death (Figure 4L–4N). We 
observed no difference in maximal heart rate in response to 
low- or high-dose epinephrine (Figure IV in the online-only 
Data Supplement), and under no circumstances were ECG 
or arrhythmic anomalies observed in control littermates. 
Although cardiac electric dysfunction may arise secondary 
to structural heart disease (hypertrophy, heart failure), we 
observed no significant differences in mean left ventricular 
ejection fraction, cardiac output, wall thickness, or other 
significant structural phenotypes between control and βII 
spectrin cKO mice (Figures VA, VB, and VIA–VIM in the 
online-only Data Supplement).
βII Spectrin cKO Myocytes Display 
Afterdepolarizations and Abnormal Calcium Waves
On the basis of the severity of observed arrhythmias in βII 
spectrin cKO mice, we examined βII spectrin cKO mouse 
Figure 2. Ankyrin-B/βII spectrin complex is blocked by human disease mutation. A, βII spectrin (green) is localized in a striated pattern in 
isolated mouse myocytes (colabeled with α-actinin, red). Scale, 10 μm. B, Radiolabeled ankyrin-B (spectrin-binding domain) associates 
with GST βII spectrin fusion protein but not GST. C and D, βII spectrin (βIIS) Ig coimmunoprecipitates ankyrin-B, NCX1, Na/K ATPase, αII 
spectrin, and actin from detergent-soluble lysates of nonfailing mouse and human left ventricle (LV). E, Human ANK2 p.R990Q arrhythmia 
variant displays aberrant βII spectrin binding. Data in inset represent equal inputs for experiments. Curves denote binding for GST-βII 
spectrin or GST alone with a concentration range of radiolabeled ankyrin-B or radiolabeled ankyrin-B R990Q (n=5 per group; *P<0.05). F, 
Primary binding data and Coomassie Blue–stained gels for fusion proteins in E. G, Ribbon structure from co-crystal structure of ankyrin-
B/βII spectrin. Human p.R990Q variant shown in green.
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ventricular myocyte action potentials. Unlike myocytes 
from control littermates, βII spectrin cKO myocytes dis-
played chaotic electric behavior even in the absence of cat-
echolamine stimulation (Figure 5A and 5C). Mean APD90 
was not different between genotypes (Figure 5I). However, 
we observed frequent spontaneous afterdepolarizations in 
βII spectrin cKO myocytes at baseline (Figure 5C and 5D). 
Afterdepolarizations were present independently of pac-
ing frequency and increased in both frequency and dura-
tion after superfusion with isoproterenol (Figure 5B, 5D, 
and 5F). We tested whether spontaneous calcium release 
potentially underlies the chaotic electric behavior of βII 
spectrin cKO myocytes by examining action potentials in 
the presence of ryanodine, an inhibitor of Ca2+ release from 
the sarcoplasmic reticulum (SR). Notably, ryanodine (100 
nmol/L) prevented afterdepolarizations in myocytes with 
or without isoproterenol (Figure 5G, 5H, and 5J). Together, 
these data strongly support a critical role for βII spectrin in 
regulating myocyte electric behavior and suggest a role for 
intracellular Ca2+ as a potential mechanism underlying the 
electric arrhythmogenic phenotypes.
Spontaneous Ca2+ waves (SCaWs) at the level of the myo-
cyte may mediate Ca2+-dependent afterdepolarizations, known 
cellular triggers for arrhythmia.15,16 Therefore, we compared 
the relative propensity of control and βII spectrin cKO myo-
cytes to generate SCaWs. βII spectrin cKO myocytes were 
significantly more likely to generate SCaWs compared with 
control myocytes (Figure 5M–5Q). SCaWs were observed 
in ≈56% of βII spectrin cKO myocytes compared with only 
≈18% of control myocytes (Figure 5K), and we observed 
<0.2 waves per wild-type myocyte versus an average of ≈2 
waves per βII spectrin cKO myocyte (P<0.05). Importantly, 
spontaneous unified Ca2+ release events (indicated by a per-
pendicular spontaneous dye front in the confocal line scans) 
were frequently observed in βII spectrin cKO myocytes but 
not in control myocytes (Figure 5O–5Q). Such perpendicular 
waves are indicative of a unified Ca2+ release within the myo-
cyte and provide evidence that the cell spontaneously reached 
the threshold that initiated an action potential. Such a unified 
spontaneous Ca2+ release was not observed in control myo-
cytes; rather, only slowly propagating waves were observed 
(Figure 5M). This SCaW-dependent phenotype provides a 
mechanism for the afterdepolarizations observed in βII spec-
trin cKO myocytes.
βII Spectrin Is Required for the Organization of 
Cardiac Membrane Proteins
We hypothesized that loss of normal calcium cycling and 
arrhythmias in βII spectrin cKO mice reflected the central 
role for βII spectrin in organizing cardiac membrane pro-
teins. To test this hypothesis, we first examined the status 
of T-tubule and SR membrane proteins critical for calcium 
release. Although we observed no difference in T-tubule 
L-type calcium channel localization or T-tubule structure 
between genotypes (Figure 6A and 6B), we observed hetero-
geneity in the subcellular localization of ryanodine receptor 
2 (RyR2), the primary cardiac SR calcium release channel in 
βII spectrin cKO myocytes (Figure 6D and Figure VII in the 
online-only Data Supplement). To further examine potential 
RyR2 heterogeneity, we analyzed RyR2 localization by total 
internal reflection fluorescence and superresolution imaging 
(see Methods in the online-only Data Supplement). In agree-
ment with the previous superresolution imaging of Baddeley 
and colleagues,17 RyR2 is localized by these techniques to 
discrete clusters of irregular shapes and sizes (Figure 6E). In 
contrast, RyR2 imaging of heterogeneous regions of interest 
(ie, red asterisk in Figure 6D, right) in βII spectrin cKO myo-
cytes showed reduced size and intensity of RyR2 clusters, as 
well as irregular intensity patterning, compared with con-
trol myocytes (Figure 6F). Consistent with these findings, 
Figure 3. Generation and validation of mice lacking βII spectrin in 
cardiomyocytes. A, Targeting strategy to generate Cre-dependent 
loss of cardiac βII spectrin. βII spectrin in brain (B) and heart (C) 
of control and βII spectrin conditional knockout (cKO) mice. D, βII 
spectrin levels in control (n=5) vs βII spectrin cKO (n=5; P<0.05) 
hearts. E, βII spectrin localization in control and βII spectrin 
cKO adult ventricular myocytes. Bar=10 μm. α-MHC indicates 
α-myosin heavy chain.
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Figure 4. Loss of βII spectrin causes 
bradycardia, rate variability, and 
arrhythmia. A and B, βII spectrin 
conditional knockout (cKO) mice display 
reduced heart rate (n=5) as assessed by 
telemetry compared with control mice 
(n=5; P<0.05). B, Heart rates of control 
and 3 βII spectrin cKO mice that show 
bradycardia and rate variability. C and 
D, ECGs from control and βII spectrin 
cKO mouse showing increased RR, 
QRS, and QT intervals. Mean data for 
parameters are shown in E through H 
(n=5 mice per genotype; P<0.05). I and 
J, Control ECG recording over 1 second 
demonstrating no R-R variability or 
heart block vs ECG recording from a βII 
spectrin cKO littermate demonstrating 
type II heart block, confirmed by P 
waves (arrowheads) without ventricular 
conduction. K, A 3-second ECG 
recording of a βII spectrin cKO mouse 
demonstrating significant R-R variability 
with heart block. L through N, βII spectrin 
cKO mice demonstrate severe arrhythmia 
phenotypes and death after injection of 
epinephrine (EPI). Examples include (L) 
4 sinus P waves (arrowheads) without 
ventricular conduction, consistent 
with type II atrioventricular block, (M) 
bigeminy, and (N) polymorphic ventricular 
arrhythmia.
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RyR2 levels were significantly reduced in βII spectrin cKO 
hearts (Figure 6G and 6H). This loss was selective for RyR2 
compared with other SR proteins in that we observed no 
difference in the expression or localization of the SR cal-
cium ATPase or in the intercalated disk protein N-cadherin 
(Figure 6C). In summary, these data define βII spectrin as 
required for the selective local organization of RyR2 calcium 
release channels. Of note, defects in local RyR2 organization 
have been linked to aberrant calcium-dependent release, 
arrhythmia, and heart failure phenotypes in humans and ani-
mal models.18–20
βII spectrin Is Required for the Expression and 
Targeting of Ankyrin-B
In addition to RyR2, βII spectrin cKO mice displayed loss 
of expression and localization of ankyrin-B in adult heart 
Figure 5. βII spectrin conditional knockout (cKO) myocytes display electric instability, afterdepolarizations, and aberrant Ca waves. Action 
potential measurements of (A and B) control and (C and D) βII spectrin cKO myocytes measured at baseline at 0.5-Hz pacing protocol 
with or without 1μmol/L isoproterenol (Iso). E and F, Electric instability was present in βII spectrin cKO myocytes independently of pacing 
frequency (shown at 1 Hz). G and H, Ryanodine (100 nmol/L) blocked abnormal electric instability of βII spectrin cKO myocytes with or 
without Iso. I, Mean APD90 of control and βII spectrin cKO myocytes with or without Iso (n>10 myocytes per genotype; P<0.05 for control 
vs control+Iso). J, Prevalence of afterdepolarizations for control and βII spectrin cKO myocytes with or without Iso and in the presence of 
ryanodine (n>10 myocytes per treatment; P<0.05 for control vs cKO at baseline; P<0.05 for control+Iso vs cKO+Iso). K and L, βII spectrin 
cKO myocytes were more likely to form spontaneous Ca2+ waves (n=27 control, n=25 βII spectrin cKO; P<0.05). M through Q, Line-scan 
images of fluo-4–loaded myocytes field stimulated at 0.5 Hz. After stimulation, myocytes were continuously monitored for spontaneous 
Ca2+ wave formation for 15 seconds. M and N, Control myocytes with no spontaneous wave activity. When waves formed, they were slow 
moving (N, dashed white line). O through Q, Spontaneous waves in βII spectrin cKO myocytes (red arrowheads). Stimulated transients are 
indicated by white arrowheads. WT indicates wild-type.
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Figure 6. βII spectrin is required for organization of calcium release units and ankyrin-B. Like control mouse myocytes, βII spectrin 
conditional knockout (cKO) myocytes display normal localization of transverse tubule Cav1.2 (A), transverse tubule organization (B; visualized 
by Di-8-ANEPPs), and intercalated disk N-cadherin (C). In contrast, ryanodine receptor 2 (RyR2) expression was reduced and heterogeneous 
in βII spectrin cKO myocytes (D, red asterisk). E and F, RyR2 expression was further analyzed by total internal reflection (continued) 
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(Figure 6I–6M). These findings were initially unantici-
pated because prior work implicates ankyrin-B as critical 
for βII spectrin targeting and localization in postnatal day 
2 neonatal cardiomyocytes.13 To define the functional rela-
tionship of ankyrin-B and βII spectrin in myocyte localiza-
tion, we evaluated βII spectrin and ankyrin-B localization 
in wild-type neonatal cardiomyocytes. As shown in Figure 
VIII in the online-only Data Supplement, striated expres-
sion of ankyrin-B precedes βII spectrin at postnatal day 1 
in mice. However, both proteins are expressed and colocal-
ized by postnatal day 3 (Figure VIII in the online-only Data 
Supplement). In support of a role of ankyrin-B in the tar-
geting of βII spectrin and in agreement with prior work,13 
ankyrin-B cKO neonatal cardiomyocytes lack βII spectrin 
expression or striation at postnatal day 1 or 3 (Figure VIII 
in the online-only Data Supplement). However, we were 
surprised to observe that, later in myocyte maturation (post-
natal day 7), ankyrin-B expression was not requisite for βII 
spectrin expression. In fact, βII spectrin expression in post-
natal day 7 myocytes is equivalent to the expression/stain-
ing observed in wild-type cardiomyocytes (Figure VIII in 
the online-only Data Supplement). This is further illustrated 
in adult myocytes in which we observe no difference in βII 
spectrin expression or localization in ankyrin-B cKO hearts 
(Figures IX and X in the online-only Data Supplement). 
Finally, βII spectrin cKO cardiomyocytes demonstrate nor-
mal expression and localization of ankyrin-B at postnatal 
day 1 and 3 but loss of ankyrin-B expression and target-
ing at postnatal day 7 (Figure VIII in the online-only Data 
Supplement). Together, these findings demonstrate a com-
plex relationship between ankyrin and βII spectrin in heart. 
More specifically, our data show that ankyrin-B plays a dom-
inant role for βII spectrin targeting in immature, developing 
myocytes, whereas in maturing and mature myocytes, βII 
spectrin assumes the dominant targeting role for ankyrin-B. 
Although we assume that this transition likely represents a 
shift in the maturity of the membrane/cytoskeletal network 
(ie, myocyte transverse tubules begin to develop ≈7 days 
in culture),21 future work will be important to better define 
the underlying mechanisms. Notably, although βII spec-
trin cKO mice displayed reduced ankyrin-B expression, we 
observed no change in the expression of ankyrin-R (Ank1) 
in βII spectrin cKO adult heart compared with control heart 
(Figure 6N and 6O). However, ankyrin-G (Ank3), a third 
ankyrin gene product expressed in heart,22 showed elevated 
expression in βII spectrin cKO hearts (Figure 6N and 6O), 
likely as a compensatory mechanism in response to reduced 
ankyrin-B levels.
βII Spectrin Is Required for Organization of 
Ankyrin-B–Associated Membrane Proteins
Ankyrin-B targets Na+/Ca2+ exchanger and Na+/K+ ATPase 
and controls regulation of dyadic proteins, including RyR2.23 
Consistent with our above findings, we observed a significant 
decrease in INCX in βII spectrin cKO myocytes (Figure 7A and 
7B). These changes were confirmed by both immunoblot and 
immunostaining in which we observed decreased expression 
of the Na/Ca exchanger and Na/K ATPase (Figure 7C–7E). 
Notably, despite the major alterations in electric activity in 
βII spectrin cKO myocytes, we did not observe differences 
in INa current (peak, activation/inactivation/late current) and 
Na
v
1.5 and connexin43 protein levels were unchanged in βII 
spectrin cKO hearts (Figure 7C and Figure XI in the online-
only Data Supplement). Together with our data on RyR2, 
these findings identify βII spectrin as essential for the local-
ization of multiple membrane proteins required for myocyte 
Ca2+ regulation.
βII Spectrin Regulates αII Spectrin and the 
Myocyte Microtubule Network
Whereas the Na/Ca exchanger and Na/K ATPase loss is 
likely related to loss of ankyrin-B targeting in βII spec-
trin cKO mice, the mechanism for RyR2 dysfunction is 
less clear. We hypothesized that this defect reflects an 
important role for βII spectrin in organizing local cardiac 
cytoskeleton. In metazoans, α and β spectrin form a sub-
membrane lattice through formation of heterotetramers via 
antiparallel N- and C-terminal interactions. However, the 
requirement of βII spectrin expression for the targeting and 
formation of the heterotetramer in heart is unknown. We 
examined the abundance of αII spectrin, an in vivo part-
ner for cardiac βII spectrin. Consistent with prior reports 
demonstrating degradation of α spectrin in the absence of 
adequate erythroid β spectrin,24–26 αII spectrin levels were 
reduced nearly 50% in βII spectrin cKO hearts (Figure 7F 
and 7G). In line with these data, we observed a reduced 
abundance of αII spectrin in βII spectrin cKO myocytes 
by immunostaining (Figure 7H–7K). On the basis of these 
data, we further investigated the integrity of the cytoskel-
eton in βII spectrin cKO myocytes. Although actin was 
unchanged in the expression or localization in βII spec-
trin cKO mice, we observed significant increases in levels 
of βI spectrin and α and β tubulin in βII spectrin cKO 
hearts by immunoblot or immunostaining (Figure 7L–7O 
and Figure XII in the online-only Data Supplement), likely 
as a compensatory response to βII spectrin deficiency and 
consistent with prior findings of tubulin remodeling in 
failing hearts.27 However, levels of desmin, an interme-
diate filament protein critical for myocyte cytoskeletal 
Figure 6 (continued). fluorescence (TIRF) and superresolution imaging. E and F, Left, Overlay of a TIRF image (red) and the corresponding 
superresolution image (green) of RyR2 in control (E) and βII spectrin cKO (F) cardiomyocytes. E and F, Right, Superresolution images 
of RyR2 in control and βII spectrin cKO myocytes. Note that data in F were collected from an area of RyR2 heterogeneity (red asterisk, 
cKO panel D, right) that illustrates reduced RyR2 cluster size and intensity. Scale bar for E and F, 1000 nm. G and H, RyR2 levels were 
significantly reduced in βII spectrin cKO myocytes (n=4 hearts per genotype; P<0.05). I through K, Ankyrin-B levels are decreased in 
the heart but not brain of βII spectrin cKO mice (n=5 hearts per genotype; P<0.05). L and M, Ankyrin-B shows reduced expression and 
abnormal targeting in βII spectrin cKO vs control myocytes (scale bar, 10 µm). N and O, Ankyrin-G but not ankyrin-R levels are decreased 
in the heart of βII spectrin cKO mice (n=5) vs control mice (n=6; P<0.05).
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Figure 7. βII spectrin deficiency results in reduced expression of ankyrin-B–associated membrane proteins and abnormal myocyte 
cytoskeletal organization. A and B, βII spectrin conditional knockout (cKO) myocytes (n=12) display reduced INCX compared with control 
mouse myocytes (n=14; P<0.05). C through E, βII spectrin cKO hearts display reduced Na/Ca exchange (NCX) and Na/K ATPase 
expression but normal expression of connexin43 (Cx43) compared with control hearts (n=4 hearts per genotype; P<0.05). F through K, βII 
spectrin cKO hearts (n=5) display reduced αII spectrin expression and localization compared with control hearts (n=5) by immunoblot and 
immunostaining (P<0.05). L through O, βII spectrin cKO hearts display a significant increase in α-tubulin expression by immunoblot and 
immunostaining with control hearts (n=5 hearts per genotype for L; P<0.05). Scale bar, 10 μm for N and O.
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infrastructure, were unchanged between control and βII 
spectrin cKO hearts (Figure XII in the online-only Data 
Supplement). In summary, these data demonstrate that 
myocytes lacking βII spectrin display significant yet 
selective cytoskeletal remodeling.
βII Spectrin cKO Mice Display Accelerated Heart 
Failure Phenotypes
Heart failure is characterized by significant electric and 
structural remodeling. On the basis of severe electric and 
structural phenotypes present in βII spectrin cKO mice at 
baseline, we hypothesized that βII spectrin cKO mice would 
display accelerated and more pronounced cardiac damage 
after induction of heart failure through transverse aortic 
constriction. Notably, unlike control littermates or sham 
βII spectrin cKO mice, βII spectrin cKO mice displayed 
cardiac arrhythmia and death associated with major struc-
tural remodeling after 6 weeks of banding (Figure 8A–8G). 
Examination of βII spectrin cKO mouse banded sections 
revealed a high prevalence of widespread myocardial degen-
eration of the left ventricular free wall and septum that was 
characterized by vacuolation, pallor, and interstitial and ven-
tricular myocyte necrosis (Figure 8A–8D). Furthermore, at 6 
weeks after banding, βII spectrin cKO mice displayed severe 
atrioventricular block, ST-segment depression, frequent 
premature ventricular complexes, and junctional rhythms 
(Figure 8E–8G). Although we observed standard pre–heart 
failure phenotypes in control mice in response to the trans-
verse aortic constriction protocol, we did not observe the 
extensive electric or structural phenotypes found in βII spec-
trin cKO littermates.
Discussion
The spectrin superfamily is composed of 2 α spectrin and 
5 β spectrin genes. Most information on spectrin function 
comes from the erythrocyte, although a growing body of 
literature points to key roles of spectrin family members 
in cytoskeletal infrastructure in complex cells. In the red 
blood cell, α and β spectrin tetramerize and form the basis 
of the submembrane ultrastructure through interactions 
with membrane proteins (eg, anion exchanger) and cyto-
skeleton (actin). Mutations in α or β spectrin in humans or 
animals result in loss of membrane integrity, spherocytosis, 
and hemolytic anemia.28 In fact, spectrin mutations are the 
cause of the most common forms of hereditary spherocyto-
sis in the white population. In complex cells, spectrins are 
critical for membrane assembly and maintenance, and both 
αII and βII spectrin–deficient mice are embryonic lethal.29,30 
βII spectrin is required for lateral membrane formation of 
columnar epithelial cells in the lung,31 and βII spectrin and 
βIV spectrin are critical for the development and mainte-
nance of the axon initial segment and nodes of Ranvier in 
the central nervous system.32–34 Little is known about the 
role of βII spectrin in heart because mice homozygous for 
βII spectrin allele deficiency die in utero.30 However, data 
from the βIII spectrin literature offer insight into the likely 
mechanisms for βII spectrin function in heart. For example, 
work from Armbrust et al35 and Stankewich and colleagues36 
demonstrates that βIII spectrin is essential for membrane 
protein targeting in the nervous system. Similar to our find-
ings in heart, targeted deletion of βIII spectrin in brain 
results in impaired assembly of the postsynaptic membrane, 
endomembrane retention of multiple synaptic proteins, and 
ataxia and seizure phenotypes.36 Moreover, human βIII spec-
trin gene mutations found in the region where βIII spectrin 
Figure 8. βII spectrin conditional knockout (cKO) 
mice show severe damage and electric phenotypes 
after aortic banding. A and B, Unlike control 
transverse aortic constriction mice, βII spectrin 
cKO mice displayed widespread myocardial 
degeneration of the left ventricular free wall and 
septum, characterized by vacuolation (arrows), 
pallor (inside circle), and necrosis of myocytes 
(hematoxylin and eosin staining; magnification, 
×200). C and D, βII spectrin cKO hearts further 
displayed increased interstitial fibrosis (blue) of 
connective tissue compared with control sections 
(vacuolation noted by arrows; magnification, ×200). 
Electric phenotypes observed in βII spectrin cKO 
and not control mice included (E) atrioventricular 
conduction defects, (F) ST-segment depression, 
and (G) intermittent premature ventricular 
complexes and junctional beats. C indicates 
coronary artery.
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associates with the dynactin subunit Arp137 cause human 
spinocerebellar ataxia (SCA5) resulting from defects in 
membrane protein (glutamate transporter EAAT4, metabo-
tropic glutamate receptor 1α) targeting.35,38 Thus, from the 
βIII spectrin data and our new findings, we hypothesize that 
βII spectrin is a critical player in membrane protein sorting 
instead of simply a static membrane structural protein. In 
fact, the demonstrated links between spectrins and dynac-
tin37 provide a logical rationale for the cell and molecular 
phenotypes observed in βII spectrin cKO animals. Although 
this study focused on the relationship between βII spec-
trin and ankyrin-B, our new data (Figure 6N and 6O) indi-
cate that it will be important to identify the relationship of 
βII spectrin with other cardiac ankyrin and spectrin gene 
products.
An important but unexpected finding of this study is the 
essential role of βII spectrin for the local organization of 
RyR2. Cardiac RyR2 is a central player for myocyte cal-
cium release, and RyR2 dysfunction has been linked to a 
broad spectrum of heart failure and arrhythmia phenotypes 
in human and animal models.39–42 Our data demonstrate a 
role of βII spectrin for both the expression and targeting 
of RyR2. However, potentially more significant, remain-
ing RyR2 populations in βII spectrin cKO myocytes are 
disorganized, displaying a heterogeneous pattern. In par-
allel, loss of βII spectrin results in reorganization of the 
microtubule network that may underlie the heterogeneous 
RyR2 distribution. Alternatively, microtubule reorganization 
may be a compensatory response of the cell to βII spectrin 
loss because we also identified increased expression of βI 
spectrin (Figure XII in the online-only Data Supplement). 
Notably, abnormal organization of the calcium release struc-
ture was also identified in a mutant mouse model harboring 
a calsequestrin mutation linked to human catecholamin-
ergic polymorphic ventricular tachycardia.42 These mice, 
like the βII spectrin cKO mice, display unstable electric 
events and significant cytosolic calcium management phe-
notypes. Beyond spectrin, junctophilin, a lipophilic mol-
ecule anchored to the junctional SR, has also been linked to 
the organization of the ryanodine receptor in heart. In fact, 
JPH2−/− mice are embryonic lethal and display an enlarged 
dyadic cleft.43 Although organization of RyR2 is altered in 
βII spectrin cKO mice, we observed normal localization and 
expression of T-tubule L-type calcium channels (Ca
v
1.2). 
Furthermore, we observed no difference in T-tubule mor-
phology between control and βII spectrin cKO mice through 
Di-8-ANEPPS imaging. Therefore, the βII spectrin path-
way appears to regulate select populations of membrane 
proteins without altering membrane morphology. It will be 
critical for future experiments to define the specific path-
ways underlying βII spectrin–dependent regulation of RyR2 
clusters. Importantly, βII spectrin–dependent regulation of 
RyR2 clusters is likely independent of ankyrin-B because 
ankyrin-B+/− mice display no defects in RyR2 expression 
or localization.10 Finally, our work supports a relationship 
between βII spectrin and the microtubule system. Because 
spectrins have previously been linked to microtubule-based 
proteins, including kinesin II and the dynein complex,44–46 
and spectrin-associated proteins, including protein 4.1R, 
have been linked to arrhythmia in animals,47 work to inte-
grate the role of the βII spectrin pathway with intracel-
lular targeting versus cytoskeletal organization will be an 
important future area of research. Likewise, because our 
data show accelerated heart failure phenotypes in βII spec-
trin cKO mice (Figure 8), it will be important to investigate 
the long-term function of βII spectrin in well-phenotyped 
human and animal disease models.
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CLINICAL PERSPECTIVE
Cardiovascular disease remains the number one cause of death in the United States and is a major and growing public health 
problem worldwide. Each year, ≈785 000 Americans experience a heart attack, and these events significantly increase the 
risk for deadly ventricular arrhythmias after myocardial infarction. Despite the fact that cardiac arrhythmias lead to >300 000 
deaths per year, current arrhythmia therapies targeting ion channels unfortunately either are suboptimal or lead to increased 
mortality. The cardiac cytoskeleton is a highly ordered array of structural, regulatory, and accessory proteins spanning from 
the plasma membrane to the nucleus. This evolved network has emerged as a central governing factor in the control of cardiac 
membrane integrity, and dysfunction in cytoskeleton and cytoskeleton-associated proteins is now directly linked to cardiac 
myopathies and dystrophies. However, the role of the cytoskeleton in normal cardiac electric function is not well resolved. 
On the basis of clinical and genetic findings from a proband with severe ventricular arrhythmia and cardiac arrest, we identi-
fied βII spectrin as critical for the organization of myocyte membrane and membrane-associated proteins. Dysfunction in 
this pathway in mice results in severe arrhythmia phenotypes associated with aberrant calcium. These findings provide a new 
mechanism for human arrhythmia and identify unexpected new roles for the cardiac cytoskeleton in human cardiovascular dis-
ease. Furthermore, these new data provide new insight into the complex mechanisms governing cardiac myocyte physiology.
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SUPPLEMENTAL MATERIAL 
 
Supplemental Methods 
 
nkyrin-B II spectrin conditional knock-out (cKO) mice. Ankyrin-B cKO mice were generated by the 
introduction of LoxP sites flanking exon 24 of Ank2.  The strategy results in the deletion of 73 bp of 
coding sequence: the splicing of exon 23-exon 25 leads to a frame shift resulting in a premature stop 
codon in exon 25.  Mice were crossed to generate pure lines of floxed mice devoid of the neomycin 
cassette. Mice were screened by PCR and Southern analyses (genOway).  Animals were crossed with 
mice expressing Cre under the cardiac promoter -myosin heavy chain (MHC-Cre) resulting in specific 
loss of ankyrin-B in adult cardiac myocytes. II spectrin cKO mice were generated by the introduction of 
LoxP sites flanking exon 3 of the gene.1 These animals were then crossed with MHC-Cre mice.  
 
Immunoblots and immunostaining.  Tissue was harvested and immediately placed into ice cold 
homogenization buffer (in mM: 50 Tris-HCl, 10 NaCl, 320 sucrose, 5 EDTA, 2.5 EGTA; supplemented 
with 1:1000 protease inhibitor cocktail and 1:1000 PMSF).  Following quantification, tissue lysates were 
analyzed on Mini-PROTEAN tetra cell (BioRad) on a 4-15% precast TGX gel (BioRad). Gels were 
transferred to a nitrocellulose membrane using the Mini-PROTEAN tetra cell (BioRad). Membranes were 
blocked for 1 hour at room temperature using a 3% BSA solution or 5% milk solution and incubated with 
primary antibody overnight at 4°C. Densitometry analysis was done using ImageLab software (BioRad). 
For all experiments, protein values were normalized against an internal loading control (actin, GAPDH, 
calsequestrin). 
 
Super-resolution image acquisition, reconstruction, and sample preparation.  Our custom built STORM 
system is based on an inverted microscope (IX71, Olympus America Inc.) with 1.49 NA 100x oil 
immersion total internal reflection fluorescence (TIRF) objective. A 647 nm diode laser (Vortran Laser 
Technology Inc.) is used to both excite and activate Alexa Fluor 647 (Life Technologies, CA). An 
EMCCD camera (iXon Ultra 897, Andor Technologies, CT) is used for image acquisition. The sample 
holder is mounted on a 3D piezo stage (Nano- LPS, Mad City Lab). An infrared 980 nm laser is used in 
combination with the piezo stage for the axial Zero Drift Correction (ZDC).2 The super-resolution image 
is reconstructed using a tracklet-based method as described.3 The effective resolution is approximately 35 
nm. Control or II spectrin cKO cardiomyocytes were labeled using RyR2 or βII-spectrin primary 
antibody as described 4 for 24 hours.  Cells were then washed and incubated with an Alexa Fluor 647 
conjugated secondary goat-anti-mouse (Life Technologies, CA) or goat-anti-rabbit secondary antibody 
(Life Technologies, CA) for 3 hours at room temperature. Glass bottom culture dishes (MatTek, MA) 
were coated with Matrigel (Corning Inc, MA, 1:6 dilution) for 45 minutes. 50 μl labeled cell suspension 
was pipetted into the dish and settled for 1 hour before washing with the imaging buffer.5 Cells were 
imaged in the imaging buffer and typically 60,000 to 80,000 frames were acquired with a frame rate of 56 
fps. 
 
Site Directed Mutagenesis. Primers were designed to insert the p.R990Q mutations into the spectrin-
binding domain of ankyrin-B in pcDNA3.1+.  Primers were used in concert with the Stratagene 
QuikChange Site-Direct Mutagenesis kit and manufacturer’s instructions.  Sequences were verified before 
experiments.  
 
Production and purification of fusion proteins. cDNAs for the WT ankyrin-B, and p.R990Q spectrin-
binding domains were PCR-amplified, cloned into pGEX6P-1 (Amersham), and sequenced to confirm 
correct sequences. To facilitate cloning, all constructs were engineered to contain 5׳ EcoRI and 3׳ XhoI 
restriction sites.  BL21(DE3)pLysS cells were transformed with the ankyrin-B pGEX6P-1 constructs and 
grown overnight at 37 °C in LB supplemented with 0.05 g/L ampicillin. The overnight cultures were 
subcultured for large-scale expression. Cells were grown to an optical density of 0.6 and induced with 1 
mM isopropyl 1-thio-α-D-galactopyranoside (IPTG) for 4 h at 37 °C.  Cells were centrifuged for 10 min 
at 8,000 x g, re-suspended in PBS, and frozen at -80 °C following re-suspension. Cells were lysed by 
thawing. The crude extract was suspended in a solution of PBS, 1 mM DTT, 1 mM EDTA, 40 g/mL 
AEBSF, 10 g/mL leupeptin, 40 g/mL benzamidine, 10 g/mL peptstatin (Lysis buffer).  Lysates were 
homogenized by sonication, centrifuged to remove cellular debris, and the supernatant incubated with 
glutathione-sepharose overnight at 4 °C.  The overnight incubation was centrifuged and washed in PBS.  
A small aliquot was separated by SDS-PAGE and Coomassie Blue stained to quantitate immobilized 
protein. 
 
 
ECG experiments.  ECG recordings of ambulatory mice were obtained using subcutaneously implanted 
radiotelemeters (DSI, St. Paul, MN).   For baseline HR analysis, continuous ECG data was collected for 1 
hour on seven separate days.  Only ECG complexes with clearly defined onset and termination signals 
were sampled.  ECG parameter measurement was performed by one individual and confirmed by two or 
more individuals. For stress tests, mice were initially injected intraperitoneally with both low dose (0.2 
mg/kg) and high dose (2 mg/kg) epinephrine.  Baseline recordings were performed prior to each injection 
for at least 5 minutes and for at least 15 minutes after the injection.    Non-sustained and sustained 
arrhythmias were identified using standard ECG analysis guidelines. Variability was assessed over a 10 
min period and expressed as the average heart rate plus standard deviation.  In a separate group of mice, 
surface ECG recordings were obtained under anesthesia with 2% isoflurane.  Three needle electrodes 
were placed subcutaneously in the standard limb configuration.  For each mouse, 15 min of continuous 
data were sampled at 4 kHz with a PowerLab 4/30 interface (AD Instruments).  Analysis was performed 
offline using LabChart 7 Pro (AD Instruments).   
 
Electrophysiology.   Membrane currents were assessed by use of an Axopatch-200B amplifier and a CV-
203BU head stage (Axon Instruments). Experimental control, data acquisition, and data analysis were 
accomplished with the use of software package PClamp 10 with the Digidata 1440A acquisition system 
(Axon Instruments).  
 
Calcium wave studies.  Isolated and fluo-4 loaded ventricular myocytes were analyzed for calcium waves.  
Myocytes were field stimulated at 0.5 Hz and upon cessation of stimulation were continuously monitored 
for spontaneous calcium wave formation for 30 seconds.   Data in Fig. 5K represents total spontaneous 
waves for each genotype over the 30 second interval. Fig. 5L represents waves/myocyte over the first 15 
seconds of observation.   
 
Action Potentials. Action potentials (APs) were performed using multiple pacing frequencies ± 
superfusion with 1M isoproterenol.  In parallel experiments, myocytes were pre-treated with 100 nM 
ryanodine.   
 
Antibodies.  The following antibodies were used in this study: mouse monoclonal anti-NCX1 (Swant), 
rabbit polyclonal anti-II spectrin, ankyrin-B, ankyrin-R, and ankyrin-G, CaMKII/CaMKII pS287 
(Badrilla), mouse monoclonal anti-Cav1.2 (Affinity Bioreagents), I spectrin (neuromab), rabbit 
polyclonal anti-Nav1.54, Na/K ATPase (Millipore), actin (Santa Cruz Biotechnology), -actinin (Sigma), 
 spectrin (Sigma),  spectrin, connexin43 (Invitrogen), -tubulin (Sigma), N-cadherin (Invitrogen), 
desmin (Sigma), GAPDH (Fitzgerald), RyR2 and SERCA2 (Affinity Bioreagents).  
 
Human variant rescue studies. Assays to evaluate human ankyrin-B mutations were performed in primary 
control and ankyrin-B cKO myocytes.  Ankyrin-B R990Q, as well as two ankyrin-B mutations previously 
shown to lack II spectrin-binding6 (DAR976AAA, A1000P) were evaluated in parallel experiments.     
In vitro binding assays. In vitro binding assays were performed as previously described using GST-fusion 
proteins and 35S-labelled in vitro translation products. Reactions were performed at 4C for 3 hours in a 
high stringency binding buffer (50 mM Tris pH 7.4, 1 mM EDTA, 1 mM EGTA, 500 mM NaCl, 0.1% 
Triton X-100), washed 5 times in a high stringency wash buffer (1 M NaCl binding buffer), separated by 
SDS-PAGE, and visualized by phosphorimaging. All binding experiments were replicated at least three 
times. 
 
Structural modeling. Analysis of ankyrin-B/spectrin interactions were performed using the high 
resolution structure of the ankyrin-B ZZUD tandem.  All structural figures were prepared using PyMOL 
(www.pymol.org).  
 
 
Echocardiography.  Transthoracic echocardiogram was performed using the Vevo 2100 (Visualsonics).  
The mice were anesthetized using 2.0 % isoflurane in 95% O2 / 5% CO2 at a rate of ~ 0.8 L/min.  
Anesthesia was maintained by administration of oxygen and ~1% isoflurane.  Electrode gel was placed on 
the ECG sensors of the heated platform and the mouse was placed supine on the platform to monitor 
electrical activity of heart.  A temperature probe was inserted into the rectum of the mouse to monitor 
core temperature of ~ 37°C.  The MS-400 transducer was used to collect the contractile parameters of the 
heart in the short axis M-mode.  Transverse aortic constriction was performed as described.7 
 
Neonatal cardiomyocyte experiments.  Experiments were performed as described, however for 
transfections, unlike previous studies in global ankyrin-B-/- myocytes in post-natal day 1 myocytes6 (done 
at P1 as global ankyrin-B mice die immediately after birth8), experiments in this manuscript were 
performed to evaluate expression in post-natal 7 day myocytes to coincide with expression and striation 
of II spectrin in the myocyte.  Based on our new findings, while II spectrin requires ankyrin-B 
expression in immature myocytes (<post-natal day 3), this relationship reverses by post-natal day 7 where 
II spectrin expression is required for ankyrin-B expression.   
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Supplemental Figure 1
Supplemental Figure 1. Localization of II spectrin in myocytes. (A) Overlay of a TIRF image
(red) and the super-resolution image (green) of βII spectrin in control myocytes. (B) Super-
resolution image of βII spectrin. Scale bar: 500 nm.
Supplemental Figure 2. Generation and validation of mice lacking ankyrin-B in ventricular cardiomyocytes.
(A) Targeting strategy to generate Cre-dependent loss of cardiac ankyrin-B. (B) Southern blot analysis of
heterozygous Neo-excised conditional knockout (MHC-Cre; Ank2f/f, cKO). Genomic DNA of tested
animals was compared with WT DNA from C57/Bl6 mouse. Spe I digested DNAs were blotted on nylon
membrane and hybridized with external 3’ probe. (C-D) Expression of ankyrin-B in tissues from ankyrin-B
cKO mouse relative to control mice (p<0.05 for ankyrin-B cKO heart compared with control heart). (E-F)
Ankyrin-B immunostaining in control and ankyrin-B cKO mouse myocytes. Bar= 10 m.
Supplemental Figure 2
Supplemental Figure 3
Supplemental Figure 3. Ankyrin-B R990Q in primary cardiomyocytes. Compared with control myocytes
(A-B), ankyrin-B cKO myocytes (C-D) at post-natal day 7 display loss of ankyrin-B expression and
membrane targeting of the Na/Ca exchanger (NCX1). (E-F) Expression of GFP-ankyrin-B is sufficient to
rescue the striated pattern of ankyrin-B and NCX1 expression in ankyrin-B cKO myocytes. (G-H) While
expressed in ankyrin-B cKO myocytes (green), GFP-ankyrin-B p.R990Q is abnormally localized and lacks
ability to rescue abnormal Na/Ca exchanger localization. As a control for ankyrin-B R990Q, two mutant
ankyrin-B polypeptides that lack II spectrin-binding activity (I-L; A1000P, DAR976AAA) were analysed
in parallel. Bar=10 m.
Supplemental Figure 4. II spectrin cKO mice display bradycardia but normal peak heart rate
response. Heart rate of conscious control mouse and II spectrin cKO mice at baseline and
following 2 mg/kg epinephrine I.P. Data represent mean heart rates of five mice/genotype
recorded by telemetry (p<0.05 for cKO mice versus control mice at baseline).
Supplemental Figure 4
Supplemental Figure 5. II spectrin cKO mice display normal cardiac function. (A) Normal baseline 
LVEF (69%) for 8 week old control mouse using M-mode end-systolic and -diastolic measurements. (B) 
Eight week II spectrin cKO mouse with baseline LVEF of 67%. 
Supplemental Figure 5
Supplemental Figure 6. II spectrin cKO mouse cardiac measurements. (A) II spectrin cKO mice
displayed decreased heart rates when compared to control mice (n=5/genotype; p<0.05). There was no
significant difference between control and II spectrin cKO mice with respect to (B) cardiac output,
(C) ejection fraction, (D) stoke volume, (F) systolic volume, (G) diastolic volume, (E) fractional
shortening and (H) systolic and (I) diastolic diameter (n=5/genotype; N.S.). (J) Control mice displayed
significantly more left ventricular posterior wall thickness (LVPW) during systole than II spectrin
cKO mice (n=5 mice/genotype, p<0.05). (K) LVPW thickness during diastole was similar between
control and II spectrin cKO mice (n=5 mice/genotype; N.S.). Intraventricular septal (IVS) thickness
did not differ between control and II spectrin cKO mice during systole (L) or diastole (M); (n=5
mice/genotype; N.S.).
Supplemental Figure 6
Supplemental Figure 7
Supplemental Figure 7. II spectrin cKO hearts display heterogeneity in RyR2 expression. RyR2
expression in (A) control, (B) II spectrin cKO, and (C) ankyrin-B cKO left ventricle heart
sections (multiple sections from n=3 hearts/genotype examined). RyR2 localization was generally
homogeneous along the Z-line of control and ankyrin-B cKO hearts (white arrowheads), we
observed heterogeneity in RyR2 expression both across myocyte sections as well as within single
II spectrin cKO myocytes (note * in panel B). Bar=10 M.
Supplemental Figure 8. Ankyrin-B targets
II spectrin in immature neonatal myocytes,
whereas II spectrin targets ankyrin-B in
mature and adult myocytes. (A-C)
Localization of ankyrin-B and II spectrin in
post-natal day 1 (P1) neonatal
cardiomyocytes from control (A), ankyrin-B
cKO (B), and II spectrin cKO myocytes
(C). Note that II spectrin expression is
minimal in the P1 myocyte whereas ankyrin-
B is expressed and striated in control
myocytes. Also note that ankyrin-B is
expressed and striated in II spectrin cKO
myocytes. (D-F) At P3, II spectrin is
expressed in control myocytes and requires
ankyrin-B for expression and localization.
(G-I) In contrast to post-natal days 1-3,
ankyrin-B is not required for II spectrin
expression or targeting. In fact, in these
maturing myocytes, similar to adult
myocytes, II spectrin is required for
ankyrin-B expression. Scale equals 10
microns in all panels.
Supplemental Figure 8
Supplemental Figure 9
Supplemental Figure 9. II spectrin levels are unchanged in hearts of ankyrin-B cKO mice.
Expression levels of II spectrin is not significantly different in protein lysates (A-B) from control
(Ctrl, n=4) versus ankyrin-B cKO hearts (n=4; p=N.S.) or by immunostaining (C-D) of adult
cardiomyocytes (red). Scale bar equals ten microns.
Supplemental Figure 10
Supplemental Figure 10. Ankyrin-B is not required for II spectrin expression or localization. II
spectrin localization (red) in control, II spectrin cKO, and ankyrin-B cKO left ventricle. Sections
are co-labeled with -actinin. Note that in C, II spectrin is normally expressed and striated in the
absence of ankyrin-B. Also note that minor background of II spectrin staining in II spectrin
cKO is small vessel (*), not ventricular myocytes. Bar=10 M.
Supplemental Figure 11. II spectrin deficiency does not alter cardiomyocyte INa. (A-B) Control (n=10)
and II spectrin cKO mouse myocytes (n=11) display no difference in INa phenotypes (N.S.).
Supplemental Figure 11
Supplemental Figure 12. II spectrin deficiency results in increased expression of I spectrin.
(A, C) I spectrin levels are increased nearly two-fold in II spectrin cKO hearts (n=5)
compared to control hearts (n=5 hearts; p<0.05). (B,C) Desmin expression levels are equivalent
between control (n=5) and II spectrin cKO hearts (n=5; p=N.S.).
Supplemental Figure 12
